Acura Pharmaceuticals, Inc. – Trademark Portfolio
Entity Type: 03
Acura Pharmaceuticals, Inc. holds 19 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 17 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include NEXAFED, AVERSION, and ACURA PHARMACEUTICALS. The owner is based in Palatine, IL.
616 N. North Court, Suite 120
Palatine, IL 60067
Showing of trademarks Trademarks
Trademark Classifications
Acura Pharmaceuticals, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Acura Pharmaceuticals, Inc. have?
Acura Pharmaceuticals, Inc. has 19 U.S. trademarks filed with the USPTO. Of these, 3 registered, 10 abandoned, 6 cancelled.
What trademark classes does Acura Pharmaceuticals, Inc. file in?
Acura Pharmaceuticals, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Acura Pharmaceuticals, Inc.'s most well-known trademarks?
Acura Pharmaceuticals, Inc.'s registered trademark portfolio includes well-known marks such as NEXAFED, AVERSION, and ACURA PHARMACEUTICALS. These are among 3 currently registered trademarks in the portfolio.
What is Acura Pharmaceuticals, Inc.'s trademark registration success rate?
Acura Pharmaceuticals, Inc. has a 16% trademark registration rate, with 3 out of 19 resolved applications resulting in successful registration. Currently, 0 applications are pending review.